Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 201-210 of 290 for lung cancer

Edit search filters
  1. Trametinib, Combination Chemotherapy, And Radiation Therapy In Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

    Rochester, MN

  2. Dose Escalation And Double-blind Study Of Veliparib In Combination With Carboplatin And Etoposide In Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  3. A Study Comparing Tarlatamab, Durvalumab, Carboplatin, And Etoposide Versus Durvalumab, Carboplatin, And Etoposide In First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

    Rochester, MN

  4. Erlotinib Hydrochloride And Cabozantinib-s-Malate Alone Or In Combination As Second Or Third Line Therapy In Treating Patients With Stage IV Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  5. TIGER-2: A Phase 2, Open-label, Multicenter, Safety And Efficacy Study Of Oral CO-1686 As 2nd Line EGFR-directed TKI In Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

    Rochester, MN

  6. A Study To Find The Recommended Dose For Further Research For VX-970 And Whole Brain Radiation Therapy To Treat Patients With Brain Metastases From Non-Small Cell Lung Cancer

    Jacksonville, FL, Rochester, MN

  7. A Phase 2, Multicenter, Study Of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib In Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) And BDX004 Positive Label

    Rochester, MN

  8. A Study To Compare The Combination Of Navlimetostat (BMS-986504) With Pembrolizumab And Chemotherapy Versus Placebo Plus Pembrolizumab And Chemotherapy In First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study Of MPDL3280A (Anti-PD-L1 Antibody) Combined With Carboplatin And Paclitaxel , And With Or Without Bevacizumab, For Patients Who Have Stage IV Non-Squamous Non-Small Cell Lung Cancer

    Jacksonville, FL

  10. Testing The Effects Of MK-3475 (Pembrolizumab) With Or Without The Usual Chemotherapy Treatment For Patients 70 Years Of Age And Older With Advanced Non-small Cell Lung Cancer

    Eau Claire, WI, La Crosse, WI

.

Mayo Clinic Footer